Conyers acted as Bermuda advisers to Roivant Sciences Ltd. in connection with a US$1.1 billion equity investment in Roivant led by the SoftBank Vision Fund. This investment, which includes existing shareholder participation, is intended to accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry.
Neil Henderson and Robert Alexander of the Bermuda office worked on the matter.